Torrent Pharmaceuticals is leaning on strong momentum in India and Brazil, with new medicine launches and a bigger sales team aimed at riding rising demand for chronic care. But pressure from tough regulation, fierce competition, and volatile currencies could still derail profits—especially in the U.S. and Germany.Read more

₹4.88k

7.7% undervalued

AnalystConsensusTarget's

Fair Value

Revenue

18.71% p.a.

Profit Margin

17.58%

Future PE

57.14x

Price in 2029

₹6.94k

Trending Discussion

Snowflake Analysis

High growth potential average dividend payer.

2 Risks

2 Rewards

View Full Analysis

Torrent Pharmaceuticals Limited Key Details

Last Reported Earnings

Mar 31, 2026

Next Reporting Earnings

n/a

: 63.92
: 75.76%
: 15.48%
: 84.2%

View Full Analysis

About 500420

Founded: 1959
Employees: 18258
CEO: Aman Mehta
WebsiteView website: www.torrentpharma.com

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.